Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials

The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and AD-related dementias (ADRD) using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management infrastructure. Working with the ACTC is a collaborative venture between the applicant, NIA, and the ACTC network. NIA and the ACTC leadership will provide guidance to potential applicants. The work of this NOFO will enable the testing of interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO intends to utilize the R01 activity code. Investigators with expertise and insights into this area of aging research are encouraged to begin to consider applying for this NOFO.